Company: PSTV
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001193125-25-258596
Chunk: 5

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Item 2
Chunk 5
---
 Company, effective September 15, 2025, covering over 51 million people throughout the United States, to provide the CNSide Test.

Our headquarters is located in Houston, Texas, in proximity to world-class cancer institutions and researchers. 

Pipeline

Our most advanced investigational drug, REYOBIQ, is a patented radiotherapy potentially useful for patients with CNS and other cancers. We announced in March 2025 that the U.S. Food and Drug Administration (“FDA”) conditionally accepted the proprietary name REYOBIQ to be used by us for our proprietary rhenium (186Re) obisbemeda. Preclinical study data describing the use of REYOBIQ